Imagine the Future of Health and Medicine: TEDMED 2012

There’s one place where you can learn about the latest innovations in technology, science, health and medical research from some of the most influential thought leaders in their fields: TEDMED.

TED, which stands for Technology, Entertainment, Design, is the world’s most famous conference on the ideas that shape the world. For the past three years, there’s been a special TED just for health and medicine — TEDMED — where passionate doers and thinkers go once a year to experience the power of new ideas, hear amazing and inspiring talks, meet innovative people, and leave transformed.

The annual TEDMED conference started today. TEDMED brings together 1500 thinkers and doers from a wide array of medical and non-medical disciplines. For the next three and a half days (April 10-13) at the Kennedy Center in Washington, D.C., this uniquely diverse community will explore the ideas, innovations and challenges that will help shape the future of health and medicine for 300 million Americans … and the world.

TEDMED is hosting over 60 speakers this year, including Francis S. Collins, the Director of the National Institutes of Health; Risa Lavizzo-Mourey, President and CEO, Robert Wood Johnson Foundation; Joel Salatin, Polyface organic farmer and author; and Ivan Oransky, Executive Editor of Reuters Health.

TEDMED has no agenda and no policy prescriptions. Instead, the organization seeks to serve the nation — and the world — by creating a safe place where people with very different ideas can come together to talk, to learn and to celebrate the amazing world we live in.

Biomarker Bulletin: April 19, 2011

Biomarker Bulletin is an occasionally recurring update of news focused on biomarkers aggregated at BiomarkerCommons.org. Biomarkers are physical, functional or biochemical indicators of normal physiological or disease processes. The individualization of disease management — personalized medicine — is dependent on developing biomarkers that promote specific clinical domains, including early detection, risk, diagnosis, prognosis and predicted response to therapy.

Biomarker Commons

The 2010 NF Conference – Connecting the Public with the Research

Neurofibromatosis (NF) encompasses a set of genetic disorders that cause benign and malignant tumors to grow along various types of nerves; it can also affect the development of bones and skin. There are three main types of NF tumors: neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2) and schwannomatosis. NF1 is the most frequent of the three; one in every 3,000 children is born with the disease.

The Children’s Tumor Foundation (CTF) is the leading non-governmental funder of scientific research into neurofibromatosis and has funded NF studies for over 25 years. Their goal is to¬†identify NF drug therapies and improve the lives of those living with the disorder. The Foundation also endeavors to increase public awareness of NF and provides resources for NF patients and their families.

2010 NF Conference